However, both the 2018 NIA-AA research framework [3] and the 2021 recommendations of the International Working Group [8] emphasize that the pathology of Alzheimer’s disease is defined by Aβ and tau biomarkers and the pathogenesis of Alzheimer’s disease is a continuous progression process ranging from cognitively unimpaired people to individuals with severe dementia. Here, MAPT is linked to early-onset autosomal dominant Alzheimer disease.